Simulations Plus (NASDAQ:SLP) Trading Down 8% – Time to Sell?

Shares of Simulations Plus, Inc. (NASDAQ:SLP) traded down 8% during trading on Thursday . The company traded as low as $33.22 and last traded at $33.02. 108,838 shares traded hands during trading, a decline of 58% from the average session volume of 258,353 shares. The stock had previously closed at $35.90.

Analyst Ratings Changes

A number of analysts have issued reports on SLP shares. Stephens began coverage on Simulations Plus in a report on Friday, November 15th. They set an “overweight” rating and a $39.00 price target for the company. KeyCorp increased their price target on shares of Simulations Plus from $35.00 to $37.00 and gave the company an “overweight” rating in a research note on Friday, January 24th. StockNews.com cut shares of Simulations Plus from a “hold” rating to a “sell” rating in a report on Monday, November 4th. Finally, William Blair reissued an “outperform” rating on shares of Simulations Plus in a research report on Wednesday, January 8th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $49.40.

Simulations Plus Stock Performance

The company has a market capitalization of $638.26 million, a PE ratio of 79.43 and a beta of 0.83. The company’s 50-day simple moving average is $31.69 and its 200-day simple moving average is $32.19.

Insider Buying and Selling

In other news, Director Walter S. Woltosz sold 20,000 shares of the firm’s stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $33.91, for a total value of $678,200.00. Following the completion of the sale, the director now directly owns 3,402,584 shares of the company’s stock, valued at $115,381,623.44. This trade represents a 0.58 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 19.40% of the company’s stock.

Institutional Trading of Simulations Plus

Institutional investors have recently added to or reduced their stakes in the stock. Janus Henderson Group PLC increased its position in shares of Simulations Plus by 7,753.3% in the fourth quarter. Janus Henderson Group PLC now owns 542,899 shares of the technology company’s stock valued at $15,141,000 after buying an additional 535,986 shares in the last quarter. Conestoga Capital Advisors LLC raised its position in Simulations Plus by 15.0% during the fourth quarter. Conestoga Capital Advisors LLC now owns 2,226,262 shares of the technology company’s stock worth $62,090,000 after acquiring an additional 290,414 shares during the last quarter. Royce & Associates LP lifted its holdings in shares of Simulations Plus by 56.6% in the fourth quarter. Royce & Associates LP now owns 371,797 shares of the technology company’s stock valued at $10,369,000 after purchasing an additional 134,381 shares in the last quarter. Nicholas Company Inc. acquired a new stake in shares of Simulations Plus in the fourth quarter valued at approximately $3,418,000. Finally, Tributary Capital Management LLC increased its stake in shares of Simulations Plus by 54.7% during the 3rd quarter. Tributary Capital Management LLC now owns 325,567 shares of the technology company’s stock worth $10,425,000 after purchasing an additional 115,122 shares in the last quarter. Hedge funds and other institutional investors own 78.08% of the company’s stock.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.